These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10521073)

  • 1. Tamoxifen-induced thrombocytopenia.
    Yao JC; Thomakos N; McLaughlin P; Buchholz TA; Kudelka AP
    Am J Clin Oncol; 1999 Oct; 22(5):529-32. PubMed ID: 10521073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen induced-thrombocytopenia: it does occur.
    Nasiroğlu N; Pamukçuoğlu M; Abali H; Oksüzoğlu B; Uner A; Zengin N
    Med Oncol; 2007; 24(4):453-4. PubMed ID: 17917098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
    Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU;
    Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
    ; Buzdar A; Howell A; Cuzick J; Wale C; Distler W; Hoctin-Boes G; Houghton J; Locker GY; Nabholtz JM
    Lancet Oncol; 2006 Aug; 7(8):633-43. PubMed ID: 16887480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
    Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
    Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment for breast cancer in the elderly.
    Marchei P; Bianco V; Pignatelli E; Chiodini S; Santini D; Carico E; Marchei M; Vecchione A
    Anticancer Res; 1996; 16(2):911-3. PubMed ID: 8687150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
    Duffy SR; Distler W; Howell A; Cuzick J; Baum M
    Am J Obstet Gynecol; 2009 Jan; 200(1):80.e1-7. PubMed ID: 19019322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tamoxifen-induced severe hypertriglyceridemia--report of 3 cases].
    Koshizuka K; Serizawa M; Hasuda N; Furuya K; Mouri N; Takano K; Matsumoto M
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1109-12. PubMed ID: 15272596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
    Mortimer JE; Urban JH
    Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation recall--another call with tamoxifen.
    Boström A; Sjölin-Forsberg G; Wilking N; Bergh J
    Acta Oncol; 1999; 38(7):955-9. PubMed ID: 10606426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
    Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
    Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue.
    Earl H; Baker P; Kerr D; Lee M; Gray R; Baum M
    BMJ; 1996 Apr; 312(7037):1036-7. PubMed ID: 8616358
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of toxicities induced by chemotherapy in breast cancer patients.
    Mehreen L; Khanam A
    Biomed Pharmacother; 2005 Oct; 59(9):524-7. PubMed ID: 16154313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
    Gianni L; Panzini I; Li S; Gelber RD; Collins J; Holmberg SB; Crivellari D; Castiglione-Gertsch M; Goldhirsch A; Coates AS; Ravaioli A;
    Cancer; 2006 Feb; 106(3):505-13. PubMed ID: 16369994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
    Prescrire Int; 2001 Jun; 10(53):76-7. PubMed ID: 11718168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.